FEHB GLP-1 coverage 2027 still includes at least one medicine for weight management. The new condition is documented behavioral therapy before and during treatment. Open Season ends December 14, 2026, so there is time to find out how your plan will apply that rule.

FEHB, the Federal Employees Health Benefits Program, provides health insurance for eligible federal employees, retirees, and families. PSHB, the Postal Service Health Benefits Program, covers eligible postal employees, postal retirees, and families.

GLP-1 means glucagon-like peptide-1, a gut hormone involved in appetite and blood sugar. Medicines acting on this signal include semaglutide, the ingredient in Wegovy, and tirzepatide, the ingredient in Zepbound.

FEHB GLP-1 coverage 2027: what changed

As of November 20, 2026, the day this article was written, the 2027 Open Season highlights from the U.S. Office of Personnel Management (OPM), which administers these benefits, confirm continued coverage. OPM says:

Plans will continue to cover at least one GLP-1 anti-obesity medication and at least two oral anti-obesity medications.

What changes is the requirement for documented participation in intensive behavioral therapy, structured support with eating habits, activity, and behavior change. It applies before and during treatment with anti-obesity medicines in both programs.

That minimum does not promise coverage for every brand. A plan can meet it without covering the particular medicine someone already uses.

What counts as intensive behavioral therapy?

Intensive behavioral therapy is often shortened to IBT. A session involves practical work on habits, rather than simply receiving a leaflet about weight loss.

The Centers for Medicare & Medicaid Services definition includes nutrition assessment, agreed goals, help overcoming barriers, and follow-up. A visit might review eating patterns, discuss an activity goal, and work through what made that goal difficult. Medicare's own payment rules are separate from FEHB's.

As of November 20, 2026, the day this article was written, OPM's Carrier Letter 2026-07, dated March 31, 2026, sets out the requirements behind the change. It describes coverage of up to 12–22 sessions a year depending on progress. That is not a universal instruction to finish 22 sessions before medication starts.

The letter allows documented in-person or virtual programs that meet its standards. A statement that someone previously tried to lose weight is insufficient by itself. An app alone does not qualify; virtual programs must include human coaching and interaction.

For someone considering semaglutide, the practical question is which program the plan accepts and how attendance gets recorded.

Where the 2027 brochure gives the real answer

The OPM plan comparison tool is on opm.gov. It identifies each FEHB brochure as the official statement of benefits. Postal members are directed to the Postal Service Health Benefits System for their comparisons.

The national rule leaves the drug choice, patient share, detailed approval criteria, and session-counting arrangements to the plan. The brochure is the starting point, together with its linked drug list and authorization policy.

A formulary is the covered-drug list. Prior authorization is the plan's review before it agrees to pay. These are the useful places to look:

Brochure section or linked document Detail to find
Prescription Drug Benefits, usually Section 5(f), and the formulary The exact Wegovy or Zepbound entry, coverage restrictions, and payment category
How You Get Care and prior approval requirements Medical records needed for starting treatment and renewing approval
Obesity treatment, preventive services, or wellness benefits Accepted therapy programs, eligible providers, virtual visits, and attendance records
Your Costs for Covered Services The medicine's patient share and any separate therapy visit charge

A copay is a fixed patient payment; coinsurance is a percentage. A deductible is spending required before specified benefits pay. The drug and counseling visits may have different payment rules.

For FEHB Wegovy coverage in 2027 or Zepbound prior authorization, the useful question names the exact product and plan option. Diabetes treatment with Ozempic or Mounjaro is a separate coverage question.

Our general open enrollment checklist covers the broader comparison steps. The federal addition is specific: who records therapy participation, what counts before treatment, and what must continue afterward?

What the therapy rule does not prove

Behavioral support has evidence behind it. An independent prevention panel, the U.S. Preventive Services Task Force, recommended intensive behavioral programs for adults with obesity in JAMA in 2018. Its review found that differences among the programs studied made it difficult to identify the most effective number of sessions.

The STEP 3 trial in JAMA, 2021, studied semaglutide alongside intensive behavioral therapy. Both the medication group and the placebo group, which received no active study drug, had 30 counseling visits over 68 weeks. It did not test an insurance requirement to attend sessions before receiving coverage.

A useful distinction remains: evidence supporting counseling does not settle every insurance rule about when it must happen.

Likewise, reports of insurers dropping GLP-1 coverage do not establish your federal plan's benefits. The insurance denial study concerns a different population, rather than predicting your FEHB decision. For a request already refused, our prior authorization denial guide explains how the written reason guides the response; federal members need their own brochure's disputed-claims procedure.

A prescribing decision is a separate decision

The prescriber's records explain the medical need and document treatment. The plan uses those records to decide payment under its rules. OPM's coverage minimum does not establish payment for a compounded prescription.

As of November 20, 2026, the day this article was written, the U.S. Food and Drug Administration (FDA) explains that it does not verify compounded drugs' safety, effectiveness, or quality before marketing.

Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The same distinction applies to compounded tirzepatide.

A licensed provider may still prescribe — that decision is between you and your doctor.

What to settle before December 14

As of November 20, 2026, the day this article was written, OPM's Open Season announcement lists November 9 through December 14, 2026, as the enrollment window. A written answer about accepted therapy, existing treatment records, and renewal requirements is useful before that deadline.

As of November 20, 2026, the day this article was written, OPM's highlights put the overall FEHB premium increase at 9.3% on average and name higher prescription spending, particularly on GLP-1s, among the drivers. A premium is the regular insurance payment; that average does not describe one person's refill bill.

Federal retirees with Medicare also have a separate Medicare GLP-1 coverage question. Using tax-advantaged savings is another issue covered in our HSA and FSA guide.

The question worth taking to the plan is concrete: “For my prescribed medicine, which therapy records must my provider submit for the first 2027 refill?”

At Promise, a licensed U.S. provider reviews every request and may prescribe or decline; not everyone qualifies.